Background
==========

Lung cancer is the most commonly diagnosed cancer and is the leading cause of cancer death in males globally, with 1.6 million newly confirmed cases and 1.4 million deaths from lung cancer annually \[[@b1-medscimonit-20-2817]\]. The incidence of lung cancer is increasing significantly and constantly \[[@b2-medscimonit-20-2817]\]. Although tobacco smoking has been established as the most important cause of lung cancer, not all lung cancers are due to smoking, and increasing evidence for the association between genetic factors and lung cancer risk has been identified by hundreds of studies \[[@b3-medscimonit-20-2817],[@b4-medscimonit-20-2817]\], suggesting that genetic factors may play a very important role in the development of lung cancer.

Epidemiologic studies have provided evidence that high consumption of vegetables and fruits is associated with a reduced risk of lung cancer \[[@b5-medscimonit-20-2817]--[@b7-medscimonit-20-2817]\], and dietary folate may be one of the micronutrients that provide protection against lung carcinogenesis \[[@b8-medscimonit-20-2817]\]. Biological functions of folate in so-called 'one-carbon metabolism' are to facilitate *de-novo* deoxynucleoside triphosphate synthesis and to provide methyl groups required for intracellular methylation reactions. Methylenetetrahydrofolate reductase (MTHFR) is a central regulatory enzyme in folate metabolism that catalyses the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the predominant circulating form of folate. Hence, MTHFR acts as a critical juncture in folate metabolism by directing folate metabolites toward the DNA methylation pathway and away from the DNA synthesis pathway. Two common functional polymorphisms of the MTHFR gene, C677T and A1298C, have been identified, and the variant genotypes are associated with low plasma folate levels and significantly diminish the MTHFR activity of individuals \[[@b9-medscimonit-20-2817]--[@b11-medscimonit-20-2817]\]. Therefore, polymorphisms in the MTHFR gene may contribute to genetic susceptibility to lung and other cancers \[[@b12-medscimonit-20-2817]\].

A series of studies have investigated the association between the MTHFR gene polymorphisms and lung cancer susceptibility, but provided controversial or inconclusive results. To lessen the impact of different genetic background, we performed this meta-analysis to assess the relationship of MTHFR gene polymorphisms with risk of lung cancer in Chinese populations.

Material and Methods
====================

Materials
---------

We searched databases containing PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure (CNKI), and Chinese Biology Medicine (CBM) up to 16 February 2014, using the following MeSH terms: ("Lung Neoplasms " \[MeSH\] or "lung cancer" or "lung tumor" or "lung carcinoma" or "carcinoma of lung") and ("MTHFR" or "methylenetetrahydrofolate reductase"). We limited the languages to English and Chinese. References from retrieved articles were also searched.

Inclusion/exclusion criteria
----------------------------

Studies included in this meta-analysis had to meet the following criteria: (1) case-control study or cohort study on associations between 2 functional polymorphisms (C677T and A1298C) in MTHFR gene and lung cancer susceptibility; (2) all patients with the diagnosis of lung cancer confirmed by pathological or histological examination; (3) sufficient published data about sample size, ORs, and their 95% CIs; (4) published in English or Chinese language; (5) the distribution of the genotypes in control groups was in the Hardy--Weinberg equilibrium; (6) all participants were Chinese. Studies were excluded when they were: (1) not case--control study or cohort study; (2) duplicate of a previous publication; (3) based on incomplete data; (4) meta-analyses, letters, reviews, or editorial articles.

Data extraction
---------------

Data were independently extracted by 2 reviewers using a standardized data extraction form. Discrepancies were resolved by discussion and if consensus was not achieved, the decision was made by all the reviewers. The title and abstract of all potentially relevant articles were screened to determine their relevance. Full articles were also scrutinized if the title and abstract were ambiguous. The following information was collected from each study: authors, journal and year of publication, study design, sample size, geographical location, ethnicity of subjects, source of controls, numbers of cases and controls, and genotype frequencies of MTHFR C677T and A1298C.

Statistical analysis
--------------------

Statistical analysis was conducted by using STATA statistical package (version 10, STATA, College Station, TX). The distributions of genotypes in controls were tested by Hardy-Weinberg equilibrium using the chi-square test. The association of polymorphisms of MTHFR and lung cancer risk was estimated by ORs with 95% CIs. The heterogeneity was tested by the Q-statistics with *P*-values \<0.1, and its possible sources of heterogeneity were assessed by subgroup analysis. Dependent on the results of heterogeneity test among individual studies, the fixed-effects model (Mantel--Haenszel) or random effects model (DerSimonian and Laird) was selected to summarize the combined ORs and their 95% CIs. The significance of the pooled ORs was determined by the z test. Publication bias was investigated with the funnel plot, in which the standard error (SE) of log OR of each study was plotted against its OR. Funnel-plot asymmetry was further assessed by Egger's linear regression test. All the *P* values were 2-sided. *P* value less than 0.05 was considered statistically significant.

Results
=======

Eligible studies
----------------

According to the inclusion criteria, 11 case-control studies \[[@b13-medscimonit-20-2817]--[@b23-medscimonit-20-2817]\] were included and 74 articles were excluded. The publication year of involved studies ranged from 2003 to 2012. The flow chart of study selection is shown in [Figure 1](#f1-medscimonit-20-2817){ref-type="fig"}. In total, 2487 lung cancer cases and 3228 healthy controls were involved in this meta-analysis, which evaluated the relationship between MTHFR polymorphism and lung cancer risk. The source of controls was mainly based on a healthy population. Ten of these studies were conducted for MTHFR C677T polymorphisms and 5 studies for MTHFR A1298C polymorphisms. The characteristics of the included studies are summarized in [Table 1](#t1-medscimonit-20-2817){ref-type="table"}.

Quantitative synthesis
----------------------

The main results of this meta-analysis and the heterogeneity test were shown in [Tables 2](#t2-medscimonit-20-2817){ref-type="table"} and [3](#t3-medscimonit-20-2817){ref-type="table"}. With respect to C677T polymorphism, no significantly elevated lung cancer risk was found in overall analyses ([Table 2](#t2-medscimonit-20-2817){ref-type="table"}). In the subgroup analysis by geographical locations, significantly increased risk was found in the population from North China (T *vs.* C: OR=1.28, 95% CI: 1.14--1.44; TT *vs.* CC: OR=1.67, 95% CI: 1.33--2.10; TT + CT *vs.* CC, OR=1.39, 95% CI=1.15--1.69; TT *vs.* CC + CT: OR=1.46, 95% CI: 1.03--2.06), was not found in the South. In the subgroup analysis by ethnicity, significantly increased risk was not found in Han populations. In the subgroup analysis by source of controls, significant association was found in population-based studies (TT *vs.* CC: OR=1.37, 95% CI: 1.14--1.65; TT *vs.* CC + CT: OR=1.25, 95% CI: 1.07--1.45).

With respect to A1298C polymorphism, no significant association with lung cancer risk was demonstrated among overall analyses and subgroup analyses by ethnicity, geographical locations, and source of controls.

Sensitive analysis and bias diagnosis
-------------------------------------

To compare the difference and evaluate the sensitivity of the meta-analyses, we used both models (the fixed effects model and random effects model) to evaluate the stability of the meta-analysis. None of the results were materially altered (data not shown). Hence, results of the sensitivity analysis suggest that the data in this meta-analysis are relatively stable and credible.

The Begg's funnel plot and Egger's test were performed to assess the publication bias of the literature. The shape of the funnel plots did not reveal obvious asymmetry (Figures not shown). Then, the Egger's test was used to provide statistical evidence of funnel plot symmetry. The Egger's test indicated that there was no obvious publication bias for MTHFR C677T in North China (T *vs.* C, t=0.12, *p*=0.925; TT *vs.* CC, t=−0.77, *p*=0.583; TT + CT *vs.* CC, t=−2.14, *p*=0.278; TT *vs.* CC + CT, t=1.21, *p*=0.441).

Discussion
==========

Although many studies analyzing the research results about the MTHFR polymorphisms and their associations with lung cancer, definite conclusions cannot be drawn. Therefore, we did this updated meta-analysis to estimate the relationships between MTHFR polymorphisms and susceptibility to lung cancer among Chinese populations only, in order to lessen the impact of different genetic background. The meta-analysis involved 11 articles, of which 10 related to C677T polymorphism and 5 related to A1298C polymorphism. The results of this meta-analysis show that the variant genotypes of the MTHFRC677T polymorphisms were significantly associated with lung cancer risk in North China.

To the best of our knowledge, there are 6 published meta-analyses of MTHFR polymorphisms and lung cancer risk. Of these, 4 meta-analyses reported that there was no association between MTHFR polymorphisms (C677T and A1298C) and lung cancer risk \[[@b24-medscimonit-20-2817]--[@b27-medscimonit-20-2817]\]. Two found that MTHFR 677TT variant genotype was associated with an increased lung cancer risk \[[@b28-medscimonit-20-2817],[@b29-medscimonit-20-2817]\], especially in Asians \[[@b28-medscimonit-20-2817]\]. Furthermore, in the meta-analysis by et al. \[[@b29-medscimonit-20-2817]\], stratified analysis by ethnicity indicated that there was no significant association observed in any genetic model of the MTHFR C677T polymorphism among Chinese populations, which is consistent with our results in overall analysis.

When we performed the subgroup analyses by ethnicity, source of controls, and geographical locations, significant association with susceptibility for the development of lung was found in North China and population-based studies, and this may be explained by several factors. First, the relationship between genes and lung cancer might vary by ethnicity. In addition, gene-environmental interaction might play an important role in susceptibility to lung cancer. Most importantly, according to the previous studies, there exist seasonal and sex differences in folate status among Chinese people \[[@b30-medscimonit-20-2817],[@b31-medscimonit-20-2817]\]. People living in North China have a higher prevalence folate concentration deficiency \[[@b30-medscimonit-20-2817]\]. Therefore, these results support the hypothesis that concomitant inadequate folate intake and impaired MTHFR activity might be important susceptibility factors for lung cancer.

Our meta-analysis has several strengths. First, we strictly followed the inclusion and exclusion criteria to reduce possible selection bias. Second, a funnel plot and Egger's linear regression test were used to assess publication bias. Third, our inclusion of non-English-language reports was important in minimizing a major potential threat to the validity of any meta-analysis-publication bias and the related threat of a language bias. Fourth, the sensitivity analysis was performed to confirm the reliability and stability of this meta-analysis. Most importantly, the impact of different genetic backgrounds was minimized by including the studies performed in Chinese populations only, and the test of Hardy-Weinberg equilibrium for distribution of the genotypes in control groups suggested that there was no significantly different genetic background among the subjects. Therefore, the 11 studies would appear to be comparable in all respects relevant to our meta-analysis.

The limitations of this meta-analysis should be acknowledged. The key limitation of this study is the lack of an assessment of folate status. However, considering stratification by geographical locations, the folate status may have limited influence on the association between MTHFR polymorphisms and lung cancer susceptibility. Another potential limitation was that our results were based on unadjusted estimates. More precise analyses can be conducted if individual data were available, which would allow for the adjustment by other covariates, including age, sex, location, race, and other factors. Thirdly, the conclusions drawn from subgroup analyses might be limited because of the small sample size.

Conclusions
===========

Our meta-analysis results support that MTHFR C677T polymorphism might contribute to individual susceptibility to lung cancer in North China. Concerning lung cancer with multifactorial etiology, to further evaluate gene--gene and gene--environment interactions on MTHFR polymorphisms and lung cancer, larger studies in selected populations with different environmental background or other risk factors are required. Such studies taking these factors into account may eventually lead to a better and more comprehensive understanding of the association between the MTHFR polymorphism and lung cancer risk.
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###### 

Characteristics of studies included in the meta-analysis.

  Authors                                                           year   Source of controls   Area        Ethnicity                                                     Genotype        C677T   A1298C                                                        
  ----------------------------------------------------------------- ------ -------------------- ----------- ------------------------------------------------------------- --------------- ------- -------- ----- ----- ----- ----- ----- ----- ---- ----- ----- ----
  Jeng et al.                                                       2003   PB                   Taiwan      Mixed[\*\*](#tfn3-medscimonit-20-2817){ref-type="table-fn"}   C677T           36      22       1     123   95    14                                 
  Zhang et al.                                                      2005   PB                   Beijing     Not stated                                                    C677T, A1298C   120     230      155   160   231   109   355   141   9    345   150   5
  Shen et al.                                                       2005   PB                   Yunnan      Not stated                                                    C677T, A1298C   33      65       18    53    42    16    71    41    2    69    34    6
  Jin et al. [\*](#tfn2-medscimonit-20-2817){ref-type="table-fn"}   2007   PB                   Guangzhou   Not stated                                                    C677T, A1298C                                            70    28    2    68    30    2
  Liu et al.                                                        2008   HB                   Nanjing     Han                                                           C677T, A1298C   157     245      98    149   265   103   341   141   18   364   142   11
  Liu et al.                                                        2009   PB                   Taiwan      Not stated                                                    C677T, A1298C   205     124      29    362   291   63    228   115   15   467   226   23
  Yao et al.                                                        2010   PB                   Hubei       Not stated                                                    C677T           27      46       20    36    51    19                                 
  Yang et al.                                                       2010   PB                   Jiangxi     Han                                                           C677T           49      52       19    62    75    28                                 
  Cui et al.                                                        2011   PB                   Shandong    Not stated                                                    C677T           58      240      140   121   325   195                                
  Cheng et al.                                                      2011   PB                   Henan       Han                                                           C677T           49      58       71    47    88    45                                 
  Ma et al.                                                         2012   HB                   Yunnan      Han                                                           C677T           20      54       46    22    28    10                                 

PB -- population-based; HB -- hospital-based.

Study excluded from the meta-analysis of MTHFR C677T; not in Hardy-Weinberg equilibrium;

Including Fukien Taiwanese, Hakka Taiwanese and Mainland Chinese.

###### 

Summary ORs and 95% CI of MTHFR C677T polymorphism and lung cancer risk.

  Analysis model                                                      Ethnicity        OR                                                            95% CI (P value)         P[a](#tfn4-medscimonit-20-2817){ref-type="table-fn"}
  ------------------------------------------------------------------- ---------------- ------------------------------------------------------------- ------------------------ ------------------------------------------------------
  T *vs.* C                                                           Overall          1.15[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.97--1.37 (0.109)       0.000
                                                                      Han              1.20[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.65--2.22 (0.566)       0.000
                                                                      Not stated       1.18[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.95--1.47 (0.143)       0.002
  TT *vs.* CC                                                         Overall          1.35[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.99--1.83 (0.058)       0.002
                                                                      Han              1.43[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.77--2.67 (0.259)       0.004
                                                                      **Not stated**   **1.42**                                                      **1.02--1.97 (0.036)**   **0.076**
  TT + CT *vs.* CC                                                    Overall          1.18[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.91--1.53 (0.205)       0.000
                                                                      Han              1.10[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       073--1.65 (0.648)        0.021
                                                                      Not stated       1.35[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.92--1.98 (0.128)       0.000
  TT *vs.* CC + CT                                                    Overall          1.25[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.99--1.57 (0.060)       0.014
                                                                      Han              1.47[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.87--2.47 (0.148)       0.005
                                                                      **Not stated**   **1.22**                                                      **1.03--1.44 (0.021)**   **0.212**
  Source of controls                                                                                                                                                          
  Population-based                                                                                                                                                            
  T *vs.* C                                                           --               1.12[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.93--1.33 (0.225)       0.001
  **TT** ***vs.*** **CC**                                             **--**           **1.37**                                                      **1.14--1.65 (0.001)**   **0.063**
  TT + CT vs. CC                                                      --               1.14[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.86--1.52 (0.349)       0.000
  **TT** ***vs.*** **CC + CT**                                        **--**           **1.25**                                                      **1.07--1.45 (0.004)**   **0.070**
  Hospital-based                                                                                                                                                              
  T *vs.* C                                                           --               1.45[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.60--3.50 (0.414)       0.000
  TT *vs.* CC                                                         --               0.49[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.09--2.66 (0.412)       0.001
  TT + CT *vs.* CC                                                    --               1.53[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.48--4.86 (0.475)       0.002
  TT *vs.* CC + CT                                                    --               1.65[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.53--5.09 (0.384)       0.006
  Subgroup by area                                                                                                                                                            
  South China[\*](#tfn6-medscimonit-20-2817){ref-type="table-fn"}                                                                                                             
  T *vs.* C                                                           --               1.09[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.86--1.39 (0.481)       0.000
  TT *vs.* CC                                                         --               1.20[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.77--1.89 (0.422)       0.007
  TT + CT *vs.* CC                                                    --               1.13[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}       0.81--1.57 (0.487)       0.000
  TT *vs.* CC + CT                                                    --               1.06                                                          0.87--1.30 (0.552)       0.115
  North China[\*\*](#tfn7-medscimonit-20-2817){ref-type="table-fn"}                                                                                                           
  **T** ***vs.*** **C**                                               **--**           **1.28**                                                      **1.14--1.44 (0.000)**   **0.293**
  **TT** ***vs.*** **CC**                                             **--**           **1.67**                                                      **1.33--2.10 (0.000)**   **0.615**
  **TT + CT** ***vs.*** **CC**                                        **--**           **1.39**                                                      **1.15--1.69 (0.001)**   **0.178**
  **TT** ***vs.*** **CC + CT**                                        **--**           **1.46**[b](#tfn5-medscimonit-20-2817){ref-type="table-fn"}   **1.03--2.06 (0.034)**   **0.031**

P value for heterogeneity;

Estimates for random effects model.

South China including Taiwan, Yunnan, Guangzhou, Nanjing, Hubei and Jiangxi;

North China including Beijing, Shandong and Henan.

###### 

Summary ORs and 95% CI of MTHFR A1298C polymorphism and lung cancer risk.

  Analysis model                                                    Ethnicity    OR     95% CI (P value)     P[a](#tfn8-medscimonit-20-2817){ref-type="table-fn"}
  ----------------------------------------------------------------- ------------ ------ -------------------- ------------------------------------------------------
  C *vs.* A                                                         Overall      1.05   0.92--1.19 (0.461)   0.845
                                                                    Not stated   1.01   0.87--1.17 (0.868)   0.878
  CC *vs.* AA                                                       Overall      1.33   0.87--2.02 (0.187)   0.449
                                                                    Not stated   1.17   0.70--1.95 (0.547)   0.381
  CC + AC *vs.* AA                                                  Overall      1.03   0.89--1.19 (0.682)   0.913
                                                                    Not stated   1.00   0.84--1.19 (0.998)   0.904
  CC *vs.* AA + AC                                                  Overall      1.31   0.86--1.99 (0.202)   0.412
                                                                    Not stated   1.16   0.70--1.92 (0.565)   0.340
  Source of controls                                                                                         
  Population-based                                                                                           
  C *vs.* A                                                         --           1.01   087--1.17 (0.868)    0.878
  CC *vs.* AA                                                       --           1.17   0.70--1.95 (0.547)   0.381
  CC + AC *vs.* AA                                                  --           1.07   0.90--1.27 (0.442)   0.949
  CC *vs.* AA + AC                                                  --           1.16   0.70--1.92 (0.565)   0.340
  Subgroup by area                                                                                           
  South China[\*](#tfn9-medscimonit-20-2817){ref-type="table-fn"}                                            
  C *vs.* A                                                         --           1.07   0.93--1.24 (0.336)   0.805
  CC *vs.* AA                                                       --           1.26   0.80--2.00 (0.317)   0.328
  CC + AC *vs.* AA                                                  --           1.07   0.90--1.27 (0.442)   0.949
  CC *vs.* AA + AC                                                  --           1.24   0.79--1.95 (0.352)   0.304

P value for heterogeneity.

South China including Taiwan, Yunnan, Guangzhou, Nanjing, Hubei and Jiangxi.
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